相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dopamine and Huntington's disease
Laetitia C. Schwab et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease
Yasuo Miki et al.
NEUROBIOLOGY OF DISEASE (2015)
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Amber L. Southwell et al.
NEUROBIOLOGY OF DISEASE (2015)
Triheptanoin improves brain energy metabolism in patients with Huntington disease
Isaac Mawusi Adanyeguh et al.
NEUROLOGY (2015)
Update on Huntington's disease: Advances in care and emerging therapeutic options
Daniel Zielonka et al.
PARKINSONISM & RELATED DISORDERS (2015)
Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
Kristoffer Sahlholm et al.
PSYCHOPHARMACOLOGY (2015)
Dopamine and Huntington's disease
Laetitia C. Schwab et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Determinants of Functional Disability in Huntington's Disease: Role of Cognitive and Motor Dysfunction
Christopher A. Ross et al.
MOVEMENT DISORDERS (2014)
Current Therapeutic Options for Huntington's Disease: Good Clinical Practice Versus Evidence-Based Approaches?
Annie Killoran et al.
MOVEMENT DISORDERS (2014)
Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing
P. Lindskov Krog et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2013)
Pharmacokinetics and metabolism of SRX246: A potent and selective vasopressin 1a antagonist
Karine M. Fabio et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline
Ralf Reilmann
MOVEMENT DISORDERS (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
One-year safety and tolerability profile of pridopidine in patients with Huntington disease
Ferdinando Squitieri et al.
NEUROLOGY (2013)
The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans
A. Hellden et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis
Petra Dunkel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2012)
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease Report of the Guideline Development Subcommittee of the American Academy of Neurology
Melissa J. Armstrong et al.
NEUROLOGY (2012)
An evidence-based approach in the treatment of Huntington's disease
T. A. Mestre et al.
PARKINSONISM & RELATED DISORDERS (2012)
Insight into the mechanism of laquinimod action
W. Brueck et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor
Elodie Kara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
Anders Lundin et al.
CLINICAL NEUROPHARMACOLOGY (2010)
The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties
Tino Dyhring et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
In vivo pharmacology of the dopaminergic stabilizer pridopidine
Henrik Ponten et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Synthesis and Evaluation of a Set of 4-Phenylpiperidines and 4-Phenylpiperazines as D2 Receptor Ligands and the Discovery of the Dopaminergic Stabilizer 4[3-(Methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16)
Fredrik Pettersson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics
Christopher A. Ross et al.
PARKINSONISM & RELATED DISORDERS (2009)
A Comparative Study of Physical Performance Measures in Parkinson's Disease
Haruko Tanji et al.
MOVEMENT DISORDERS (2008)
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat
Sridhar Natesan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
FJ Marshall et al.
NEUROLOGY (2006)
Pharmacological management of Huntington's disease: An evidence-based review
Raphael M. Bonelli et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity
C Nehl et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2004)
Huntington's disease - Clinical correlates of disability and progression
N Mahant et al.
NEUROLOGY (2003)
Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease
P Klivenyi et al.
JOURNAL OF NEUROCHEMISTRY (2003)
分享论文
